Skip to main content

Precision BioSciences, Inc.

corporate_fare Company Profile

Precision BioSciences, Inc.

DTIL·NASDAQ·Life Sciences·CIK 0001357874

We are a clinical stage gene editing company that uses our proprietary ARCUS platform to develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is distinct from other technologies due to its cutting mechanism, smaller size, and simpler structure. This platform is utilized to create in vivo gene editing therapies for complex gene edits, including gene insertion (adding DNA to a gene to enable expression or add function), elimination (removing a genome, such as viral DNA), and excision (removing a large part of a defective gene by delivering two ARCUS nucleases within a single adeno-associated virus ("AAV")). Genome editing is a biotechnology process that removes, inserts, or repairs a segment of DNA at a specific location within a cell's genome. While early applications focused on genetic research, advancements in genome editing technologies are now enabling their use in treating or preventing diseases by editing DNA. This process is achieved by delivering a DNA cutting enzyme, known as an endonuclease, to a targeted segment of genetic code.

Precision BioSciences, Inc. (NASDAQ:DTIL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for DTIL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for DTIL spans FWP, 8-K, 10-Q, DEF 14A.

Recent high-impact activity:

  • $125M Stock Sale Priced at $7.75, Just Above the Last Close
  • Precision BioSciences Launches Stock and Pre-Funded Warrant Offering on Heels of Hepatitis B Data
  • Precision BioSciences' PBGENE-HBV Hits 100% pgRNA Clearance at 0.4 mg/kg, Moves to Phase 2
  • DSMB Clears PBGENE-DMD Safety Review, Allowing Expanded Dosing in Duchenne Trial
  • PBGENE-HBV Eliminates cccDNA Evidence in 92% of Evaluable Hep B Patients, Phase 2 Set for Q1 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$34.26M
Net Income
-$45.72M
Diluted EPS
-$3.56
Op. Cash Flow
-$65.84M
Free Cash Flow
-$65.93M
Operating Income
-$52.15M
Cash & Equivalents
$110.82M
Debt / Equity
0.00×
Net Margin
-133.4%
Shares Outstanding
24.09M sh
Source: 10-K · filed 2026-03-12 · accession 0001628280-26-017019

Short Interest & Short Volume

10.52 days to cover

FINRA reported short interest of 2,096,967 shares in DTIL as of the October 30, 2026 settlement, a 11.0% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 73.6% of DTIL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,096,967 shares as of October 30, 2026
Change vs prior period▼ 11.0%
Days to cover10.52 at avg daily volume of 199,360
Daily short volume (FINRA facilities)73.6% of 182,508 shares on November 20, 2026
5-day average short volume72.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for DTIL, detected from its recent SEC filings · based on capital-structure filings through 2026-11-06.

1 recent capital raise

Offering Terms Confirmed · Net Proceeds and Fees

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with D →
$7.4
52-week range · as of 2026-11-05 $3.53 – $9.62
Market cap
$206.72M
Volume
429.8K (1.1× avg)
3-mo avg 393.6K
Live data · 2026-11-22 03:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DTIL - Latest Insights

DTIL
Nov 05, 2026, 7:10 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $7.73
Real-time Price: $7.40 info
Change: -$0.330 (-4%) info
Market Cap: $206.724M info
DTIL
Nov 05, 2026, 7:07 AM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $7.40 info
Change: -$1.10 (-13%) info
Market Cap: $206.724M info
DTIL
Nov 05, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $7.40 info
Change: -$0.990 (-12%) info
Market Cap: $206.724M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.57
Real-time Price: $7.40 info
Change: -$1.17 (-14%) info
Market Cap: $206.724M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $7.40 info
Change: -$0.990 (-12%) info
Market Cap: $206.724M info
DTIL
Nov 03, 2026, 8:58 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.33
Real-time Price: $7.40 info
Change: +$0.070 (+0.95%) info
Market Cap: $206.724M info
DTIL
Nov 03, 2026, 8:09 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.91
Real-time Price: $7.40 info
Change: -$0.5122 (-6%) info
Market Cap: $206.724M info
DTIL
Aug 24, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.95
Real-time Price: $7.40 info
Change: -$1.55 (-17%) info
Market Cap: $206.724M info
DTIL
Aug 06, 2026, 7:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.85
Real-time Price: $7.40 info
Change: +$0.550 (+8%) info
Market Cap: $206.724M info
DTIL
Aug 06, 2026, 7:16 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.85
Real-time Price: $7.40 info
Change: +$0.550 (+8%) info
Market Cap: $206.724M info
DTIL
Aug 06, 2026, 7:16 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $7.40 info
Change: +$0.550 (+8%) info
Market Cap: $206.724M info
DTIL
Jul 01, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.94
Real-time Price: $7.40 info
Change: -$0.540 (-7%) info
Market Cap: $206.724M info
DTIL
Jun 16, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.31
Real-time Price: $7.40 info
Change: +$1.09 (+17%) info
Market Cap: $206.724M info
DTIL
May 27, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.00
Real-time Price: $7.40 info
Change: -$0.600 (-7%) info
Market Cap: $206.724M info
DTIL
May 26, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.58
Real-time Price: $7.40 info
Change: -$0.180 (-2%) info
Market Cap: $206.724M info
DTIL
May 05, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $7.78
Real-time Price: $7.40 info
Change: -$0.380 (-5%) info
Market Cap: $206.724M info
DTIL
May 05, 2026, 7:20 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.78
Real-time Price: $7.40 info
Change: -$0.380 (-5%) info
Market Cap: $206.724M info
DTIL
May 05, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.78
Real-time Price: $7.40 info
Change: -$0.380 (-5%) info
Market Cap: $206.724M info
DTIL
Apr 08, 2026, 7:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $6.20
Real-time Price: $7.40 info
Change: +$1.20 (+19%) info
Market Cap: $206.724M info
DTIL
Mar 27, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $6.02
Real-time Price: $7.40 info
Change: +$1.38 (+23%) info
Market Cap: $206.724M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets